Akeso sets durability bar as immuno-oncology 2.0 race heats up

FierceBiotechFDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board

FierceBiotechFDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

10x Genomics NewsVanguard Portfolio Management reports 6.98M TXG shares (NASDAQ: TXG) - Stock Titan

Endpoints NewsFDA debuts plan to collect real-time clinical trial data

Endpoints NewsThe crown for healthcare admin tech is still up for grabs

Endpoints NewsPfizer delays patent cliff for blockbuster Vyndamax

Endpoints NewsHikma and Amarin's generic drug case heads to Supreme Court arguments

BioPharma DivePfizer deals extend patent life for a top-selling rare disease drug

FierceBiotechErasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death

FierceBiotechIncyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off Rinvoq

FierceBiotechAbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

FierceBiotechProtagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits